✓ Translated by DotMD AI Clinical Council Source: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40712928 ↗

Phase III Randomized Trial: Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial

Original Paper Title: “Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • This longitudinal analysis of PROs in a large trial of breast and boost radiotherapy demonstrates an overall decrease in the number of patient-reported moderate/marked AEs up to 5-years following radiotherapy.
  • Study Design & Sample: Phase III Randomized Trial published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: IMPORT HIGH demonstrated non-inferiority of simultaneous integrated boost against sequential boost for ipsilateral breast tumour relapse. Key clinical takeaway: This longitudinal analysis of PROs in a large trial of breast and boost radiotherapy demonstrates an overall decrease in the number of patient-reported moderate/marked AEs up to 5-years following radiotherapy.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2025-10-15; Phase III Randomized Trial; Rigor 82/100): This longitudinal analysis of PROs in a large trial of breast and boost radiotherapy demonstrates an overall decrease in the number of patient-reported moderate/marked AEs up to 5-years following radiotherapy.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: facial-injuries-and-disorders → Condition: biodefense-and-bioterrorism →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40712928: Phase III Randomized Trial: Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial

3 of 3 Free Questions Remaining